A 14-year-old boy who presented with debilitating lethargy was shown to have an elevated serum ferritin of 572 mg/L and a C282Y homozygous HFE genotype. Liver iron concentration was measured non-invasively by magnetic resonance imaging, which revealed a liver iron concentration of 59 mmol/g dry weight (children's reference range o14). The early phenotypic expression was further investigated by screening genomic DNA for the presence of co-inherited mutations in genes responsible for non-HFE haemochromatosis. Coding regions and splice sites in genes encoding hepcidin and haemojuvelin were sequenced and previously described mutations in ferroportin 1 and transferrin receptor 2 genes were screened. Although no mutations were found, the most likely cause for the early expression is the presence of novel mutations or gene(s).
Introduction
Clinical symptoms of C282Y homozygous HFE-related haemochromatosis usually manifest in the third to sixth decades of life. 1 If the onset of symptoms occurs before the age of 20 years, the clinical course is typically more severe and is usually due to mutations genetically distinct from HFE-related haemochromatosis. 1 Juvenile haemochromatosis, a much rarer disease than HFE haemochromatosis, is characterized by endocrine and cardiac dysfunction and has been associated with mutations in either the hepcidin (HAMP) 2 or haemojuvelin (HJV) 3 genes. Recent reports have also documented exacerbation of phenotypic expression of HFE-related haemochromatosis in cases where mutations in either HAMP or HJV genes were co-inherited. 4--6 We describe a case of C282Y homozygous HFE-related haemochromatosis in whom clinical symptoms manifested at the age of 14 years and who underwent screening for possible mutations in four genes known to cause non-HFE haemochromatosis.
Case report Proband studies
The proband was a boy aged 14 years who presented to a general practitioner for the investigation of debilitating lethargy. Full blood counts and liver function tests, including alanine aminotransferase, were normal on three occasions; thyroid function and virology testing for hepatitis A, B and C and parvovirus were negative, and Epstein-Barr virus was consistent with past infection. Iron studies were performed to exclude iron de¢-ciency as a possible cause of the lethargy. However, as shown in Table 1 , he had a signi¢cantly elevated serum transferrin saturation of 51% and a ferritin value of 572 mg/L, and gene testing for HFE haemochromatosis was requested. The policy of the laboratory is to discourage HFE gene testing in children under the age of 18 years, on the grounds that clinical expression of C282Y homozygous HFE genotype usually does not occur until middle age. The patient was referred to a paediatrician who con¢rmed the elevated transferrin saturation and ferritin results, and HFE gene testing revealed a C282Y homozygous HFE genotype (Table 1) . There were no cardiac or endocrine complications observed on clinical examination.
A liver biopsy was not performed, as current recommendations reserve liver biopsy for C282Y homozygous individuals who ful¢l at least one of the following criteria; a serum ferritin level 41000 mg/L, an abnormal serum aminotransferase level, or hepatomegaly. 7 Liver iron concentration was obtained non-invasively by magnetic resonance imaging and revealed a liver iron concentration of 59 mmol/g dry weight. The reference limit for adults is relatively well studied with general agreement for a limit of 33 mmol/g dry weight. 8 Although there are comparatively few data on paediatric ranges, a recent study reported a reference limit of 1.0 mmol/g dry weight/year of age for hepatic iron index, 8 suggesting an upper reference limit of 14 mmol/g dry weight for a 14-year old.
The patient was referred for therapeutic venesection on a fortnightly basis, with each venesection of approximately 450 mL considered to remove 0.25 g of iron. Total body iron was calculated 9 from the liver iron concentration and body weight (58 kg) to be 2 g, requiring an estimated eight venesection episodes. Progress was monitored by two further liver iron estimations by magnetic resonance imaging, which gave results of 47 mmol/g dry weight after four episodes and 10 mmol/g dry weight on completion of all eight venesection episodes. The lethargy was noted to have improved at this stage. As more data on liver iron estimations by magnetic resonance imaging is accumulated, it may be demonstrated to be a generally e¡ective tool, as it proved to be in this particular case, both to predict the number of venesection episodes and to monitor progress during the course of venesection.
Family studies
Serum iron indices were examined and HFE haemochromatosis gene testing carried out on both parents and older siblings ( Table 1 ). The sister, aged 21 years, was also C282Y homozygous with a raised transferrin saturation; however, the serum ferritin was normal. The only other abnormality in the family was a raised transferrin saturation of 64% in the father, suggesting that if modi¢er gene(s) were present in the proband, they were more likely to have been inherited paternally. Both parents and the remaining sibling shared identical HFE genotypes; they were all heterozygous for the C282Y mutation.
Materials and methods
Serum iron and transferrin levels, both measured in mmol/L, were measured on an automated analyser (Hitachi 917, Roche, Tokyo, Japan) and percentage transferrin saturation was calculated according to the formula (serum iron/[(2 Â transferrin) Â 100]). Serum ferritin was measured by chemiluminescence immunoassay (Architect i2000, Abbott, Chicago, USA). Genotype analysis for the C282Y and H63D HFE mutations was performed by realtime polymerase chain reaction (PCR) on the LightCycler (Roche, Mannheim, Germany).
Liver iron concentration was obtained non-invasively by in vivo imaging with a clinical 1.5 T magnetic resonance imaging unit using the hydrogen proton transverse relaxation rate or R2 imaging parameter. HAMP and HJV genes were PCR ampli¢ed and sequenced using the primers listed in Table 2 . The presence of previously described ferroportin 1 (Fpn1) and transferrin receptor 2 (TfR2) gene mutations was determined by PCR ampli¢cation using the primers listed in Table 2 and either directly sequenced or digested with restriction enzymes and resultant fragments resolved on agarose gels.
PCR reactions were carried out using 50 ng of genomic DNA in 50 mL reactions using New England Biolabs Taq DNA polymerase and containing 10 pmol of each primer and 200 mM of deoxynucleoside triphosphates (dNTPs). For sequences with high G þ C content, either 1 M betaine or 5% dimethyl sulphoxide (DMSO) was included in the reaction. The following temperature pro¢le was used for all PCRs: 951C for 2 min, followed by 35 cycles of 941C 30 s, 551C 30 s, 721C 30 s, with a ¢nal elongation step of 721C 5 min. The resulting PCR products were puri¢ed using the Eppendorf Perfect Prep kit according to the manufacturer's instructions. Sequencing reactions were performed using 1 mL of puri¢ed PCR product and 2 pmol of primer in a 10 mL reaction using Applied Biosystems Big Dye Terminator v3.1 according to the manufacturer's instructions.
Discussion
We considered the possibility that the unusually early clinical penetrance may be the result of co-inheritance of mutations in a modifying gene, which might accelerate iron loading. A UK study examined two kindreds and reported synergistic interactions between mutations in the HAMP gene and the C282Y mutation, and a digenic inheritance model was proposed where the severity of the C282Y homozygous phenotype could be modi¢ed by heterozygosity for HAMP mutations. 4 A French group have screened a large cohort of C282Y Table 2 Mutations and primer sequences used to detect non-HFE gene mutations
Gene
Exon/mutation Primer sequences Method for detecting mutations
CTT GGA GAG GAG CAG GTT GC Sequencing ACT GGT GCT TGC AAG GCA GG ACC CTG CAG TGG GTG TAC TC MspI digest TAT GCG CAC GTT GTA CAT GCG homozygous patients for mutations in HAMP 5 and HJV 6 genes and have reported that both are capable of operating as modi¢er genes to exacerbate the iron burden.
Genomic DNA from the proband was used to examine the following candidate modifying genes known to cause most cases of non-HFE haemochromatosis: ferroportin disease, 11, 12 TfR2-associated haemochromatosis, 13, 14 hepcidin-associated haemochromatosis 2 and haemojuvelin-associated haemochromatosis, 3 as shown in Table 2 . The entire coding regions and splice sites for HAMP and HJVgenes were sequenced. In addition, the most common disease causing mutations in Fpn1 and TfR2 were screened for using a combination of sequence analysis and restriction enzyme digestion. No sequence changes or mutations were detected.
In conclusion, although we did not detect any mutations in the likely non-HFE-modifying genes, we cannot rule out a previously undescribed mutation in TfR2 or Fpn1 or possible mutations in non-coding regions of HAMP or HJV. It is also possible that asyet-unidenti¢ed modifying gene(s) could operate as modi¢ers of iron loading. While we acknowledge that the early onset of haemochromatosis in this patient could have been caused solely by inheriting the C282Y homozygous state, we nevertheless favour the presence of non-HFE-modifying gene(s) as the cause.
This report highlights the phenotypic variability in HFE-associated haemochromatosis. Our patient presented with clinical features at an age normally associated only with the juvenile form of the disease. This boy clearly bene¢ted from early diagnosis and treatment of iron overload, con¢rming that some children require early diagnosis and treatment to prevent further clinical complications.
